ARCALIS, Inc.
Minamisoma, Fukushima, Japan
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (3)
○ EMA GMP
○ MHRA GMP
Quick Facts: ARCALIS, Inc.
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Minamisoma, Fukushima, Japan
- Modalities
- mRNA, LNP/Formulation, Plasmid DNA, Self-amplifying mRNA (saRNA)
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About ARCALIS, Inc.
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesmRNA, LNP/Formulation, Plasmid DNA, Self-amplifying mRNA (saRNA)
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (4 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press3 articles
Broad modality coverage (4 modalities)
Recent News 3 articles
Axcelead and A2 Healthcare Announce Strategic Partnership to Accelerate Drug R&D - Business Wire
Arcturus Therapeutics, a U.S. developer of mRNA medicines, has established a Japanese subsidiary in Chiba Prefecture as a joint venture with Axcelead, Inc., and is setting up a manufacturing plant in Minamisoma City, Fukushima Prefecture | 2022 - Events & - jetro.go.jp
Meiji Seika Pharma invests in ARCALIS to boost production of mRNA vaccines in Japan - BioSpectrum Asia
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
BioCina
Adelaide, Australia
Biologics (Microbial), Plasmid DNA, mRNA, LNP, Sterile Fill-Finish, Recombinant Proteins, Vaccines, Biosimilars, High Potency/Oncology Injectables, Blow-Fill-Seal
Pfizer CentreOne
Kalamazoo, MI · McPherson, KS
Signal Score: 91.5
Biologics, mRNA
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 88.0
AAV, Lentiviral, Plasmid, mRNA
Aldevron
Fargo, ND
Signal Score: 85.3
Plasmid, mRNA
BioNTech (Mfg Services)
Mainz, DE · Marburg, DE
Signal Score: 84.8
mRNA